Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With VKORC1 1173C
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Differences in the performance of suggested warfarin dosing algorithms among different ethnicities and genotypes have been reported; this necessitates the development of an algorithm with enhanced performance for specific population groups. Previous warfarin dosing algorithms underestimated warfarin doses in VKORC1 1173C carriers. We aimed to develop and validate a new warfarin dosing algorithm for Korean patients with VKORC1 1173C. Methods: A total of 109 patients carrying VKORC1 1173CT (N=105) or 1173CC (N=4) were included in this study. Multiple regression analysis was performed to deduce a new dosing algorithm. Following literature searches for genotype-guided warfarin dosing algorithms, 21 algorithms were selected and evaluated using the correlation coefficient (ρ) of actual dose and estimated dose, mean error, and root mean square error. Results: The developed algorithm is as follows: maintenance dose (mg/week)=exp [3.223−0.009×(age)+0.577×(body surface area [BSA])+0.178×(sex)−0.481×(CYP2C9 genotype)+0.227×(VKORC1 genotype)]. Integrated variables explained 44% of the variance in the maintenance dose. The predicted and actual doses showed moderate correlation (ρ=0.641) with the best performance with a mean error of -1.30 mg/week. The proportion of underestimated groups was 17%, which was lower than with the other algorithms. Conclusions: This is the first study to develop and validate a warfarin dosing algorithm based on data from VKORC1 1173C carriers; it showed superior predictive performance compared with previously published algorithms.
Abstract
Background: Differences in the performance of suggested warfarin dosing algorithms among different ethnicities and genotypes have been reported; this necessitates the development of an algorithm with enhanced performance for specific population groups. Previous warfarin dosing algorithms underestimated warfarin doses in VKORC1 1173C carriers. We aimed to develop and validate a new warfarin dosing algorithm for Korean patients with VKORC1 1173C. Methods: A total of 109 patients carrying VKORC1 1173CT (N=105) or 1173CC (N=4) were included in this study. Multiple regression analysis was performed to deduce a new dosing algorithm. Following literature searches for genotype-guided warfarin dosing algorithms, 21 algorithms were selected and evaluated using the correlation coefficient (ρ) of actual dose and estimated dose, mean error, and root mean square error. Results: The developed algorithm is as follows: maintenance dose (mg/week)=exp [3.223−0.009×(age)+0.577×(body surface area [BSA])+0.178×(sex)−0.481×(CYP2C9 genotype)+0.227×(VKORC1 genotype)]. Integrated variables explained 44% of the variance in the maintenance dose. The predicted and actual doses showed moderate correlation (ρ=0.641) with the best performance with a mean error of -1.30 mg/week. The proportion of underestimated groups was 17%, which was lower than with the other algorithms. Conclusions: This is the first study to develop and validate a warfarin dosing algorithm based on data from VKORC1 1173C carriers; it showed superior predictive performance compared with previously published algorithms.
참고문헌 (35)
- Shaw K, "Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy", Ther Drug Monit, 37, pp.428~436 (2015)
- 김솔잎, "Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines", Annals of Laboratory Medicine, 37(2), pp.180~193 (2017), 대한진단검사의학회
- Verhoef TI, "Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon", Br J Clin Pharmacol, 77, pp.626~641 (2014)
- Huang SW, "Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose : a prospective study in Chinese patients", Pharmacogenet Genomics, 19, pp.226~234 (2009)
- Peng Q, "Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients", Pharmacogenomics, 16, pp.1465~1474 (2015)
- Mina Yang, "Evaluation of 16 genotype-guided Warfarin Dosing Algorithms in 310 Korean Patients Receiving Warfarin Treatment: Poor Prediction Performance in VKORC1 1173C Carriers", Clinical Therapeutics, 38(12), pp.2666~2674.e1 (2016), Elsevier BV[DOI]
- Saffian SM, "Warfarin dosing algorithms underpredict dose requirements in patients requiring ≥7 mg daily: a systematic review and meta-analysis", Clin Pharmacol Ther, 102, pp.297~304 (2017)
- Limdi NA, "Race influences warfarin dose changes associated with genetic factors", Blood, 126, pp.539~545 (2015)
- Rieder MJ, "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
- Patillon B, "Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans", PLoS One, 7, pp.e53049~ (2012)
- D’Andrea G, "A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin", Blood, 105, pp.645~649 (2005)
- Cho HJ, "Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients", Pharmacogenomics, 8, pp.329~337 (2007)
- Simon R, "Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification", J Natl Cancer Inst, 95, pp.14~18 (2003)
- 이경아, "Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients", Yonsei Medical Journal, 57(3), pp.635~640 (2016), 연세대학교의과대학[DOI]
- Cho HJ, "Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation", Clin Ther, 33, pp.1371~1380 (2011)
- Kim HS, "Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement", Pharmacogenet Genomics, 19, pp.103~112 (2009)
- Wei M, "A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation", Thromb Haemost, 107, pp.1083~1091 (2012)
- Miao L, "Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients", Eur J Clin Pharmacol, 63, pp.1135~1141 (2007)
- Ohno M, "Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients", Eur J Clin Pharmacol, 65, pp.1097~1103 (2009)
- Takahashi H, "Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans", Pharmacogenet Genomics, 16, pp.101~110 (2006)
- Avery PJ, "A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy", Clin Pharmacol Ther, 90, pp.701~706 (2011)
- Sconce EA, "The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen", Blood, 106, pp.2329~2333 (2005)
- Wadelius M, "The largest prospective warfarin-treated cohort supports genetic forecasting", Blood, 113, pp.784~792 (2009)
- Lenzini P, "Integration of genetic, clinical, and INR data to refine warfarin dosing", Clin Pharmacol Ther, 87, pp.572~578 (2010)
- International Warfarin Pharmacogenetics Consortium, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)
- Gage BF, "Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin", Clin Pharmacol Ther, 84, pp.326~331 (2008)
- Perini JA, "Pharmacogenetics of warfarin : development of a dosing algorithm for Brazilian patients", Clin Pharmacol Ther, 84, pp.722~728 (2008)
- Anderson JL, "Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation", Circulation, 116, pp.2563~2570 (2007)
- Alzubiedi S, "Pharmacogenetic-guided warfarin dosing algorithm in African-Americans", J Cardiovasc Pharmacol, 67, pp.86~92 (2016)
- You JH, "Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients", J Thromb Thrombolysis, 31, pp.113~118 (2011)
- Tan SL, "Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement", Pharmazie, 67, pp.930~937 (2012)
- Chen J, "A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients", PLoS One, 9, pp.e105250~ (2014)
- Choi JR, "Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients", J Hum Genet, 56, pp.290~295 (2011)
- Mukaka MM, "Statistics corner : A guide to appropriate use of correlation coefficient in medical research", Malawi Med J, 24, pp.69~71 (2012)
- Horne BD, "Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy", Thromb Haemost, 107, pp.232~240 (2012)